Bryan Garnier - BIONTECH (BNTX.O) BIONTECH: Revised sales projections for Comirnaty with significant room for upside | BUY Top Picks | USD135 VS. USD130 (+17%)

Report

Bryan Garnier

Olga Smolentseva

BIONTECH: Revised sales projections for Comirnaty with significant room for upside | BUY Top Picks | USD135 VS. USD130 (+17%)

BIONTECH - BUY Top Picks | USD135 VS. USD130 (+17%)
Revised sales projections for Comirnaty with significant room for upside

TP increased to USD135 following the financial update
Comirnaty keeps up with the positive news

06/04/2021 4 EN

Underlying

BIONTECH

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Olga Smolentseva

Other Reports on these Companies

Bryan Garnier

BIONTECH - BUY | USD308 While minimally disclosed, clinical data support preclinical evidence for BA.4/5 booster

October 14, 2022 October 14, 2022 1 EN

Bryan Garnier

BIONTECH: ESMO late-breaking presentation to substantiate the CAR-T case | BUY | USD308

BIONTECH - BUY | USD308 ESMO late-breaking presentation to substantiate the CAR-T case

September 8, 2022 September 8, 2022 1 EN

Bryan Garnier

BIONTECH - BUY | USD308 Omicron-adapted booster sets a precedent for EUA approval based on preclinical data

FDA approves bivalent booster setting the precedent of preclinical data use Another lawsuit targeting mRNA technology, but we do not expect a significant impact on net revenues

September 1, 2022 September 1, 2022 1 EN

Edenred: re-accelerating in Q1 2024

Edenred has reported robust sales numbers with operating revenue re-accelerating to +16.9%, well ahead of market expectations at 14.2%. Resilient demand and the largely under-penetrated market addressed by the firm hint at a continuation in the growth trends observed today, and add weight to our or

23h / 5m 23h / 5m 1 EN

Paul Charpentier

Paul Charpentier

Planisware to start trading on 18th April with a EUR1.1bn valuation

On Tuesday, Planisware (not covered), a French B2B software publisher, announced it would float its shares on the Paris stock exchange on 18th April at a valuation of EUR1.1bn. As a reminder, the listing comes after the IPO project was called off in October 2023 due to unfavourable market condition

23h / 11m 23h / 11m 1 EN

Loic Morvan ... (+2)

Loic Morvan
Paul Rouviere

LVMH: Q1 might be the low point for F&LG growth

As anticipated, LVMH reported a quite poor Q1 2024 performance, with a 3% sales growth (at same FX), but at least in line with consensus expectations and with no dramatic trend. Furthermore, we remind investors that LVMH faced a fairly demanding comparison basis (sales were up 17% in Q1 23). We rei

April 17, 2024 April 17, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BIONTECH: Revised sales projections for Comirnaty with significant room for upside | BUY Top Picks | USD135 VS. USD130 (+17%)

BIONTECH - BUY | USD308 While minimally disclosed, clinical data support preclinical evidence for BA.4/5 booster

BIONTECH: ESMO late-breaking presentation to substantiate the CAR-T case | BUY | USD308

BIONTECH - BUY | USD308 Omicron-adapted booster sets a precedent for EUA approval based on preclinical data

Edenred: re-accelerating in Q1 2024

Planisware to start trading on 18th April with a EUR1.1bn valuation

LVMH: Q1 might be the low point for F&LG growth

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe